gvtcx

NHS National Framework Agreement for the supply of Adalimumab Injection 1 April 2023

NHS England Published 24 Mar 2023 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£264,003,000
Statuscomplete
Category (CPV) 33600000
Deadline28 Nov 2022
Contract start1 Apr 2023
Contract end28 Feb 2026
Procedureopen
SME suitableYes
OCIDocds-b5fd17-f074e643-f848-4b2d-aec8-e624b3fc10e0

Awards (6)

This procurement was awarded to 6 suppliers. Values shown are per-award; the notice total is £264,003,000.

SupplierValueDateStatus
Abbvie Ltd shared £264,003,228 3 Mar 2023 active
Amgen Ltd shared £264,003,228 3 Mar 2023 active
Biogen shared £264,003,228 3 Mar 2023 active
Celltrion Healthcare United Kingdom Limited shared £264,003,228 3 Mar 2023 active
Fresenius Kabi Limited shared £264,003,228 3 Mar 2023 active
Sandoz Ltd shared £264,003,228 3 Mar 2023 active

description

Project Title: NHS National Framework Agreement for the supply of Adalimumab Injection 1 April 2023

Offer reference number: CM/PHR/22/5660

CM/PHR/22/5660/01 - NHS Framework Agreement for the supply of Adalimumab Injection to South of England. Period of framework: 1 April 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5660/02 - NHS Framework Agreement for the supply of Adalimumab Injection to the Midlands and East. Period of framework: 1 April 2023 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5660/03 - NHS Framework Agreement for the supply of Adalimumab Injection to London. Period of framework: 1 April 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

CM/PHR/22/5660/04 - NHS Framework Agreement for the supply of Adalimumab Injection to the North of England. Period of framework: 1 April 2023 to 28 February 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

1 notice published against this procurement.

PublishedTypeRegimeNotice
24 Mar 2023 Award (award) · a6b9f437-01c6-49a7-a10f-e629b7cdf660-627683

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.